United Therapeutics Corporation
A maker of medicines for rare lung conditions such as pulmonary arterial hypertension, sold under brands like Remodulin and Tyvaso. Founder Martine Rothblatt launched the company in 1996 after her young daughter was diagnosed with the disease, turning a personal fight into a career. The firm is also known for a futuristic goal: gene-edited pig organs for human transplants, an approach that has made it a familiar name in xenotransplantation.
Sold 238.8K
Granted 7.45M · Bought 150.1K · Sold 7.51M
Granted 2.63M · Sold 1.85M
Granted 1.07M · Sold 817.2K
Granted 135.8K · Sold 60.2K
Granted 2.40M · Sold 1.97M
Granted 589.3K · Sold 556.0K
Granted 172.8K · Sold 130.9K
Granted 272.2K · Sold 191.6K
Granted 13.4K
Granted 316.7K · Sold 209.2K
Granted 10.1K · Sold 5.1K
Granted 59.4K · Sold 59.4K
Granted 326.5K · Sold 246.7K
Granted 67.1K · Sold 55.2K
Granted 272.3K · Sold 195.8K
Granted 306.5K · Bought 21 · Sold 228.8K
Granted 2.0K · Sold 2.0K
Granted 241.4K · Sold 63.2K
Granted 768.0K · Sold 768.0K
Granted 1.2K · Sold 1.1K
Granted 174.0K · Sold 174.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Lilly Eli & Co10% owner · 4 transactions | — | 5.25Mas of Jul 2011 | — | — | 238.8K |
| Rothblatt Martine AChairperson & CEO, Director · 6055 transactions | — | 49.6K | 7.45M | 150.1K | 7.51M |
| Mahon Paul AEVP & GENERAL COUNSEL · 1280 transactions | — | 45.2K | 2.63M | — | 1.85M |
| Benkowitz MichaelPRESIDENT AND COO · 667 transactions | — | 36.5K | 1.07M | — | 817.2K |
| Thompson Tommy GDirector · 95 transactions | — | 30.3K | 135.8K | — | 60.2K |
| Jeffs RogerPresident & Co-CEO, Director · 650 transactions | — | 27.3Kas of Mar 2016 | 2.40M | — | 1.97M |
| Edgemond JamesCFO AND TREASURER · 539 transactions | — | 25.5K | 589.3K | — | 556.0K |
| Giltner RichardDirector · 61 transactions | — | 20.6Kas of Jul 2025 | 172.8K | — | 130.9K |
| Kurzweil RayDirector · 68 transactions | — | 17.6K | 272.2K | — | 191.6K |
| Klein Katherine JDirector · 5 transactions | — | 13.4Kas of Mar 2024 | 13.4K | — | — |
| Sullivan Louis WDirector · 115 transactions | — | 6.4K | 316.7K | — | 209.2K |
| Mesa NildaDirector · 20 transactions | — | 5.0K | 10.1K | — | 5.1K |
| Hadeed Fred TEVP, Business Development · 36 transactions | — | 4.8Kas of Aug 2006 | 59.4K | — | 59.4K |
| Dwek RaymondDirector · 208 transactions | — | 4.8Kas of Apr 2025 | 326.5K | — | 246.7K |
| Olian Judy D.Director · 45 transactions | — | 4.2K | 67.1K | — | 55.2K |
| Causey ChristopherDirector · 366 transactions | — | 4.2K | 272.3K | — | 195.8K |
| Patusky ChristopherDirector · 222 transactions | — | 2.6K | 306.5K | 21 | 228.8K |
| Maxwell LindaDirector · 2 transactions | — | 2.0Kas of May 2022 | 2.0K | — | 2.0K |
| Zaccardelli DavidEVP & Chief Operating Officer · 106 transactions | — | 1.5Kas of May 2016 | 241.4K | — | 63.2K |
| Ferrari John MaximCFO · 199 transactions | — | 407as of Feb 2015 | 768.0K | — | 768.0K |
| Malcolm JanDirector · 11 transactions | — | 125 | 1.2K | — | 1.1K |
| Gray R PaulDirector · 69 transactions | — | 0as of Nov 2013 | 174.0K | — | 174.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -15.18M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.